ADAM8 and cancer: These studies describe the isolation of a novel class of highly specific human ADAM8 dual MP and DI inhibitor mAbs and the identification of ADP2 and ADP13 mAbs as promising candidates for the future development of the first ADAM8-targeted cancer intervention.